BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9607037)

  • 1. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi.
    Anders RF; Crewther PE; Edwards S; Margetts M; Matthew ML; Pollock B; Pye D
    Vaccine; 1998; 16(2-3):240-7. PubMed ID: 9607037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design.
    Amante FH; Crewther PE; Anders RF; Good MF
    J Immunol; 1997 Dec; 159(11):5535-44. PubMed ID: 9548494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.
    Xu H; Hodder AN; Yan H; Crewther PE; Anders RF; Good MF
    J Immunol; 2000 Jul; 165(1):389-96. PubMed ID: 10861076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.
    Burns JM; Flaherty PR; Romero MM; Weidanz WP
    Vaccine; 2003 May; 21(17-18):1843-52. PubMed ID: 12706668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
    Burns JM; Flaherty PR; Nanavati P; Weidanz WP
    Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes.
    Crewther PE; Matthew ML; Flegg RH; Anders RF
    Infect Immun; 1996 Aug; 64(8):3310-7. PubMed ID: 8757869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
    Rainczuk A; Scorza T; Spithill TW; Smooker PM
    Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of Plasmodium chabaudi malaria: strategies for assembly of immunologically active peptides.
    Salvatore D; Hodder AN; Zeng W; Brown LE; Anders RF; Jackson DC
    Vaccine; 2002 Oct; 20(29-30):3477-84. PubMed ID: 12297393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
    Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
    Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1.
    Fu Y; Shearing LN; Haynes S; Crewther P; Tilley L; Anders RF; Foley M
    J Biol Chem; 1997 Oct; 272(41):25678-84. PubMed ID: 9325291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.
    Rainczuk A; Scorza T; Smooker PM; Spithill TW
    Infect Immun; 2003 Aug; 71(8):4506-15. PubMed ID: 12874330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with a Plasmodium chabaudi adami multivalent DNA vaccine cross-protects A/J mice against challenge with P. c. adami DK and virulent Plasmodium chabaudi chabaudi AS parasites.
    Scorza T; Grubb K; Cambos M; Santamaria C; Tshikudi Malu D; Spithill TW
    Int J Parasitol; 2008 Jun; 38(7):819-27. PubMed ID: 18062974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.
    Scorza T; Grubb K; Smooker P; Rainczuk A; Proll D; Spithill TW
    Infect Immun; 2005 May; 73(5):2974-85. PubMed ID: 15845504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to erythrocytic stages of malarial parasites.
    Long CA; Daly TM; Kima P; Srivastava I
    Am J Trop Med Hyg; 1994; 50(4 Suppl):27-32. PubMed ID: 7909653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
    Rotman HL; Daly TM; Long CA
    Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed allele malaria vaccines: host protection and within-host selection.
    Barclay VC; Chan BH; Anders RF; Read AF
    Vaccine; 2008 Nov; 26(48):6099-107. PubMed ID: 18804509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying variation in the potential for antibody-mediated apparent competition among nine genotypes of the rodent malaria parasite Plasmodium chabaudi.
    Fairlie-Clarke KJ; Allen JE; Read AF; Graham AL
    Infect Genet Evol; 2013 Dec; 20():270-5. PubMed ID: 24056014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
    Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
    Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.